Trials / Completed
CompletedNCT00633789
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 597 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib
Conditions
- Advanced Non-small Cell Lung Cancer
- Transitional Cell Carcinoma
- Soft Tissue Sarcoma
- Gastric/Esophageal Adenocarcinoma
- Pancreatic Cancer Including Ampulla of Vater
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | brivanib | Tablets, Oral, 800 mg, once daily, until progression |
| DRUG | Placebo | Tablets, Oral, 0 mg, once daily, until progression |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-02-01
- Completion
- 2012-12-01
- First posted
- 2008-03-12
- Last updated
- 2015-10-09
Locations
25 sites across 9 countries: United States, Argentina, Belgium, Canada, France, Germany, Netherlands, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT00633789. Inclusion in this directory is not an endorsement.